Department of Economics and Business Economics

Protocol and rationale: A 24-week double-blind, randomized, placebo controlled trial of the efficacy of adjunctive garcinia mangostana linn. (Mangosteen) pericarp for schizophrenia

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Alyna Turner, IMPACT Strategic Research Centre, University of Newcastle Faculty of Medicine and Health Sciences, University Melbourne
  • ,
  • John J. McGrath
  • Olivia M. Dean, IMPACT Strategic Research Centre, University Melbourne
  • ,
  • Seetal Dodd, IMPACT Strategic Research Centre, University Melbourne
  • ,
  • Andrea Baker, Park Centre for Mental Health
  • ,
  • Susan M. Cotton, University Melbourne, Orygen
  • ,
  • James G. Scott, Queensland Centre for Mental Health Research, Park Centre for Mental Health, Metro North Mental Health Service, Faculty of Medicine, The University of Queensland
  • ,
  • Bianca E. Kavanagh, IMPACT Strategic Research Centre
  • ,
  • Melanie M. Ashton, IMPACT Strategic Research Centre, University Melbourne
  • ,
  • Adam J. Walker, IMPACT Strategic Research Centre
  • ,
  • Ellie Brown, IMPACT Strategic Research Centre, University Melbourne, Orygen
  • ,
  • Michael Berk, IMPACT Strategic Research Centre, University Melbourne, Orygen

Objective: Garcinia mangostana Linn., commonly known as mangosteen, is a tropical fruit with a thick pericarp rind containing bioactive compounds that may be beneficial as an adjunctive treatment for schizophrenia. The biological underpinnings of schizophrenia are believed to involve altered neurotransmission, inflammation, redox systems, mitochondrial dysfunction, and neurogenesis. Mangosteen pericarp contains xanthones which may target these biological pathways and improve symptoms; this is supported by preclinical evidence. Here we outline the protocol for a double-blind randomized placebo-controlled trial evaluating the efficacy of adjunctive mangosteen pericarp (1,000 mg/day), compared to placebo, in the treatment of schizophrenia. Methods: We aim to recruit 150 participants across two sites (Geelong and Brisbane). Participants diagnosed with schizophrenia or schizoaffective disorder will be randomized to receive 24 weeks of either adjunctive 1,000 mg/day of mangosteen pericarp or matched placebo, in addition to their usual treatment. The primary outcome measure is mean change in the Positive and Negative Symptom Scale (total score) over the 24 weeks. Secondary outcomes include positive and negative symptoms, general psychopathology, clinical global severity and improvement, depressive symptoms, life satisfaction, functioning, participants reported overall improvement, substance use, cognition, safety and biological data. A 4-week post treatment interview at week 28 will explore post-discontinuations effects. Results: Ethical and governance approvals were gained and the trial commenced. Conclusion: A positive finding in this study has the potential to provide a new adjunctive treatment option for people with schizophrenia and schizoaffective disorder. It may also lead to a greater understanding of the pathophysiology of the disorder.

Original languageEnglish
JournalClinical Psychopharmacology and Neuroscience
Volume17
Issue2
Pages (from-to)297-307
Number of pages11
ISSN1738-1088
DOIs
Publication statusPublished - 2019

    Research areas

  • Garcinia mangostana Linn, Mangosteen, Oxidative stress, Psychotic disorder, Schizophrenia, Treatment clinical trial

See relations at Aarhus University Citationformats

ID: 154019223